{"transactions":[{"id":803710,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":45982,"kind":"person","name":"Francois Eric","position":1,"cik":"0001656125","reported_name":"Francois Eric","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-21T23:46:43.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":1823278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) August 13, 2026 or (ii) the achievement of a specified clinical milestone in 2026, in each case subject to the reporting person's continuous service through the applicable vesting date."}],"balance_after":1823278,"derivative":{"exercise_price":0.055,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":1823278},"source":{"system":"sec-edgar","filing":"0001213900-26-046329","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1656125/000121390026046329/ownership.xml","form_type":"4"}},{"id":942828,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T21:30:22.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":690900,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":690900,"derivative":{"exercise_price":0.055,"exercise_date":"2026-01-07","expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":690900},"source":{"system":"sec-edgar","filing":"0001213900-26-002947","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390026002947/ownership.xml","form_type":"4"}},{"id":941797,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":50834,"kind":"person","name":"KUCHARCHUK ANDREW ALBERT","position":1,"cik":"0001654127","reported_name":"KUCHARCHUK ANDREW ALBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T21:30:12.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":1162099,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1162099,"derivative":{"exercise_price":0.055,"exercise_date":"2026-01-07","expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":1162099},"source":{"system":"sec-edgar","filing":"0001213900-26-002948","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654127/000121390026002948/ownership.xml","form_type":"4"}},{"id":941798,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69617,"kind":"person","name":"Rolfe Lindsey","position":1,"cik":"0001650504","reported_name":"Rolfe Lindsey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T16:30:24.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":690900,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":690900,"derivative":{"exercise_price":0.055,"exercise_date":"2026-01-07","expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":690900},"source":{"system":"sec-edgar","filing":"0001213900-26-002949","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650504/000121390026002949/ownership.xml","form_type":"4"}},{"id":942455,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69684,"kind":"person","name":"Pierce Kristen","position":1,"cik":"0002039649","reported_name":"Pierce Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T16:30:21.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":1612099,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1612099,"derivative":{"exercise_price":0.055,"exercise_date":"2026-01-07","expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":1612099},"source":{"system":"sec-edgar","filing":"0001213900-26-002945","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2039649/000121390026002945/ownership.xml","form_type":"4"}},{"id":942003,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69655,"kind":"person","name":"Patel Shami","position":1,"cik":"0001378251","reported_name":"Patel Shami","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T16:30:19.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":690900,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":690900,"derivative":{"exercise_price":0.055,"exercise_date":"2026-01-07","expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":690900},"source":{"system":"sec-edgar","filing":"0001213900-26-002946","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378251/000121390026002946/ownership.xml","form_type":"4"}},{"id":941941,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T16:30:17.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":1612099,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1612099,"derivative":{"exercise_price":0.055,"exercise_date":"2026-01-07","expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":1612099},"source":{"system":"sec-edgar","filing":"0001213900-26-002951","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390026002951/ownership.xml","form_type":"4"}},{"id":941988,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T16:30:15.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":4530997,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4530997,"derivative":{"exercise_price":0.055,"exercise_date":"2026-01-07","expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":4530997},"source":{"system":"sec-edgar","filing":"0001213900-26-002952","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390026002952/ownership.xml","form_type":"4"}},{"id":941806,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T16:30:13.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":690900,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":690900,"derivative":{"exercise_price":0.055,"exercise_date":"2026-01-07","expiration_date":"2036-01-06","underlying":"Common Stock","underlying_shares":690900},"source":{"system":"sec-edgar","filing":"0001213900-26-002950","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000121390026002950/ownership.xml","form_type":"4"}},{"id":1128646,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T21:09:45.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":9326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the 1/3 time-based portion of an award of options to purchase 27,979 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through March 4, 2026, with the remaining portion subject to performance conditions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 1/3 time-based portion of an award of options to purchase 27,979 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through March 4, 2026, with the remaining portion subject to performance conditions."}],"balance_after":9326,"derivative":{"exercise_price":0.4454,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":9326},"source":{"system":"sec-edgar","filing":"0001213900-25-050131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390025050131/ownership.xml","form_type":"4"}},{"id":1127178,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":50834,"kind":"person","name":"KUCHARCHUK ANDREW ALBERT","position":1,"cik":"0001654127","reported_name":"KUCHARCHUK ANDREW ALBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T20:57:58.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":152500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in equal monthly installments through June 4, 2027."}],"balance_after":152500,"derivative":{"exercise_price":0.4454,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":152500},"source":{"system":"sec-edgar","filing":"0001213900-25-050105","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654127/000121390025050105/ownership.xml","form_type":"4"}},{"id":1127185,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T17:08:19.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":9326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the 1/3 time-based portion of an award of options to purchase 27,979 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through March 4, 2026, with the remaining portion subject to performance conditions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 1/3 time-based portion of an award of options to purchase 27,979 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through March 4, 2026, with the remaining portion subject to performance conditions."}],"balance_after":9326,"derivative":{"exercise_price":0.4454,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":9326},"source":{"system":"sec-edgar","filing":"0001213900-25-050128","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000121390025050128/ownership.xml","form_type":"4"}},{"id":1127179,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69617,"kind":"person","name":"Rolfe Lindsey","position":1,"cik":"0001650504","reported_name":"Rolfe Lindsey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T17:06:49.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":9326,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the 1/3 time-based portion of an award of options to purchase 27,979 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through March 4, 2026, with the remaining portion subject to performance conditions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 1/3 time-based portion of an award of options to purchase 27,979 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through March 4, 2026, with the remaining portion subject to performance conditions."}],"balance_after":9326,"derivative":{"exercise_price":0.4454,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":9326},"source":{"system":"sec-edgar","filing":"0001213900-25-050123","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650504/000121390025050123/ownership.xml","form_type":"4"}},{"id":1127476,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69655,"kind":"person","name":"Patel Shami","position":1,"cik":"0001378251","reported_name":"Patel Shami","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T17:05:40.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":11693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the 1/3 time-based portion of an award of options to purchase 35,079 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through March 4, 2026, with the remaining portion subject to performance conditions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 1/3 time-based portion of an award of options to purchase 35,079 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through March 4, 2026, with the remaining portion subject to performance conditions."}],"balance_after":11693,"derivative":{"exercise_price":0.4454,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":11693},"source":{"system":"sec-edgar","filing":"0001213900-25-050121","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378251/000121390025050121/ownership.xml","form_type":"4"}},{"id":1127468,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T17:04:25.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":61843,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the 1/3 time-based portion of an award of options to purchase 185,529 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through December 4, 2025, with the remaining portion subject to performance conditions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 1/3 time-based portion of an award of options to purchase 185,529 shares, vesting in equal monthly installments on the 4th of each month from July 4, 2025 through December 4, 2025, with the remaining portion subject to performance conditions."}],"balance_after":61842,"derivative":{"exercise_price":0.4454,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":61842},"source":{"system":"sec-edgar","filing":"0001213900-25-050116","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390025050116/ownership.xml","form_type":"4"}},{"id":1127426,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T17:02:49.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":122549,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in equal monthly installments through May 30, 2027."}],"balance_after":122549,"derivative":{"exercise_price":0.4454,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":122549},"source":{"system":"sec-edgar","filing":"0001213900-25-050113","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390025050113/ownership.xml","form_type":"4"}},{"id":1127952,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69684,"kind":"person","name":"Pierce Kristen","position":1,"cik":"0002039649","reported_name":"Pierce Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-02T17:01:19.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":154841,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in equal monthly installments through June 4, 2027."}],"balance_after":154841,"derivative":{"exercise_price":0.4454,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":154841},"source":{"system":"sec-edgar","filing":"0001213900-25-050110","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2039649/000121390025050110/ownership.xml","form_type":"4"}},{"id":1177494,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2025-04-04T19:12:50.000Z","date":"2025-03-31","kind":"exercise","planned":false,"acquired":true,"shares":294460,"price":0.0001,"value":29.446,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time on or after the date of issuance for an exercise price of $0.0001 per share, for shares of common stock of the Issuer."}],"balance_after":11660,"derivative":{"exercise_price":0.0001,"exercise_date":"2025-02-07","underlying":"Common Stock","underlying_shares":294460},"source":{"system":"sec-edgar","filing":"0001213900-25-029111","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390025029111/ownership.xml","form_type":"4"}},{"id":1177493,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-04T19:12:50.000Z","date":"2025-03-31","kind":"exercise","planned":false,"acquired":true,"shares":294460,"price":0.0001,"value":29.446,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On March 28, 2025, Mr. Atwood exercised Pre-Funded Warrants (the \"Pre-Funded Warrants\") and directed the issuance of the shares of common stock of CERo Therapeutics Holdings, Inc. (the \"Issuer\") to the Atwood-Edminster Trust dtd 4-2-2000 (the \"Trust\"). Mr. Atwood and his wife are the managers of the LLC and the trustees of the Trust. Accordingly, Mr. Atwood may be deemed to have beneficial ownership of the securities held directly by the LLC.."}],"balance_after":490534,"source":{"system":"sec-edgar","filing":"0001213900-25-029111","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390025029111/ownership.xml","form_type":"4"}},{"id":1220949,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-06T21:18:14.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":17923,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the 50% time-based portion of an award of options to purchase 35,846 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 50% time-based portion of an award of options to purchase 35,846 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions."}],"balance_after":17923,"derivative":{"exercise_price":1.43,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":17923},"source":{"system":"sec-edgar","filing":"0001213900-25-021192","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390025021192/ownership.xml","form_type":"4"}},{"id":1219018,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69617,"kind":"person","name":"Rolfe Lindsey","position":1,"cik":"0001650504","reported_name":"Rolfe Lindsey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-06T16:16:51.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":17923,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the 50% time-based portion of an award of options to purchase 35,846 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 50% time-based portion of an award of options to purchase 35,846 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions."}],"balance_after":17923,"derivative":{"exercise_price":1.43,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":17923},"source":{"system":"sec-edgar","filing":"0001213900-25-021190","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650504/000121390025021190/ownership.xml","form_type":"4"}},{"id":1219031,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-06T16:16:13.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":17923,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the 50% time-based portion of an award of options to purchase 35,846 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 50% time-based portion of an award of options to purchase 35,846 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions."}],"balance_after":17923,"derivative":{"exercise_price":1.43,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":17923},"source":{"system":"sec-edgar","filing":"0001213900-25-021188","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000121390025021188/ownership.xml","form_type":"4"}},{"id":1219344,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69655,"kind":"person","name":"Patel Shami","position":1,"cik":"0001378251","reported_name":"Patel Shami","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-06T16:15:36.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":14936,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the 50% time-based portion of an award of options to purchase 29,871 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 50% time-based portion of an award of options to purchase 29,871 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions."}],"balance_after":14936,"derivative":{"exercise_price":1.43,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":14936},"source":{"system":"sec-edgar","filing":"0001213900-25-021187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378251/000121390025021187/ownership.xml","form_type":"4"}},{"id":1219293,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-06T16:14:58.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":14936,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the 50% time-based portion of an award of options to purchase 29,871 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 50% time-based portion of an award of options to purchase 29,871 shares, vesting on the twelve month anniversary of the grant date, with the remaining portion subject to performance conditions."}],"balance_after":14936,"derivative":{"exercise_price":1.43,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":14936},"source":{"system":"sec-edgar","filing":"0001213900-25-021183","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390025021183/ownership.xml","form_type":"4"}},{"id":1219316,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-06T16:10:56.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":119486,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the 50% time-based portion of an award of options to purchase 238,971 shares, vesting on the nine month anniversary of the grant date, with the remaining portion subject to performance conditions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the 50% time-based portion of an award of options to purchase 238,971 shares, vesting on the nine month anniversary of the grant date, with the remaining portion subject to performance conditions."}],"balance_after":119486,"derivative":{"exercise_price":1.43,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":119486},"source":{"system":"sec-edgar","filing":"0001213900-25-021180","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390025021180/ownership.xml","form_type":"4"}},{"id":1244871,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T23:02:04.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 1, 2024, the Reporting Person was granted an option to purchase 255,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On February 24, 2025, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to the second installment, resulting in the vesting of 127,500 shares."}],"balance_after":255000,"derivative":{"exercise_price":0.1,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0001213900-25-017518","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390025017518/ownership.xml","form_type":"4"}},{"id":1242434,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69617,"kind":"person","name":"Rolfe Lindsey","position":1,"cik":"0001650504","reported_name":"Rolfe Lindsey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T18:06:06.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 1, 2024, the Reporting Person was granted an option to purchase 255,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On February 24, 2025, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to the second installment, resulting in the vesting of 127,500 shares."}],"balance_after":255000,"derivative":{"exercise_price":0.1,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0001213900-25-017524","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650504/000121390025017524/ownership.xml","form_type":"4"}},{"id":1242754,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69655,"kind":"person","name":"Patel Shami","position":1,"cik":"0001378251","reported_name":"Patel Shami","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T18:03:50.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 11, 2024, the Reporting Person was granted an option to purchase 255,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On February 24, 2025, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to the second installment, resulting in the vesting of 127,500 shares."}],"balance_after":255000,"derivative":{"exercise_price":0.0951,"expiration_date":"2034-10-10","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0001213900-25-017521","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378251/000121390025017521/ownership.xml","form_type":"4"}},{"id":1242718,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T17:59:49.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":1275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 1, 2024, the Reporting Person was granted an option to purchase 2,550,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On February 24, 2025, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to the second installment, resulting in the vesting of 1,275,000 shares."}],"balance_after":2550000,"derivative":{"exercise_price":0.1,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":1275000},"source":{"system":"sec-edgar","filing":"0001213900-25-017515","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390025017515/ownership.xml","form_type":"4"}},{"id":1242436,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T17:57:17.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 1, 2024, the Reporting Person was granted an option to purchase 255,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On February 24, 2025, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to the second installment, resulting in the vesting of 127,500 shares."}],"balance_after":255000,"derivative":{"exercise_price":0.1,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0001213900-25-017510","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000121390025017510/ownership.xml","form_type":"4"}},{"id":1242672,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-26T17:54:18.000Z","date":"2025-02-24","kind":"grant","planned":false,"acquired":true,"shares":254000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 1, 2024, the Reporting Person was granted an option to purchase 508,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On February 24, 2025, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to the second installment, resulting in the vesting of 254,000 shares."}],"balance_after":508000,"derivative":{"exercise_price":0.1,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":254000},"source":{"system":"sec-edgar","filing":"0001213900-25-017505","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390025017505/ownership.xml","form_type":"4"}},{"id":1278559,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to Purchase Shares of Common Stock","published_at":"2025-02-07T17:23:22.000Z","date":"2025-02-07","kind":"grant","planned":false,"acquired":true,"shares":204080,"price":1.9599,"value":399976.392,"ownership":{"direct":false,"nature":"By GVN, LLC"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 7, 2025, pursuant to a Securities Purchase Agreement, dated February 5, 2025, the reporting persons purchased Pre-Funded Warrants, which are exercisable at any time on or after the date of issuance for an exercise price of $0.0001 per share, for shares of common stock of CERo Therapeutics Holdings, Inc. (the \"Issuer\"), and an equal number of Warrants, which will become exercisable immediately upon the Issuer's receipt of stockholder approval (the \"Stockholder Approval Date\") for an exercise price of $1.96 per share, for shares of the Issuer's common stock. The aggregate purchase price for each pair of Pre-Funded Warrants and Warrants was $1.9599. The Warrants will expire on the fifth anniversary of the Stockholder Approval Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 7, 2025, pursuant to a Securities Purchase Agreement, dated February 5, 2025, the reporting persons purchased Pre-Funded Warrants, which are exercisable at any time on or after the date of issuance for an exercise price of $0.0001 per share, for shares of common stock of CERo Therapeutics Holdings, Inc. (the \"Issuer\"), and an equal number of Warrants, which will become exercisable immediately upon the Issuer's receipt of stockholder approval (the \"Stockholder Approval Date\") for an exercise price of $1.96 per share, for shares of the Issuer's common stock. The aggregate purchase price for each pair of Pre-Funded Warrants and Warrants was $1.9599. The Warrants will expire on the fifth anniversary of the Stockholder Approval Date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"GVN, LLC (the \"LLC\") is a limited liability company of which the sole member is the Atwood-Edminster Trust dtd 4-2-2000 (the \"Trust\"). Mr. Atwood and his wife are the managers of the LLC and the trustees of the Trust. Accordingly, Mr. Atwood may be deemed to have beneficial ownership of the securities held directly by the LLC."}],"balance_after":204080,"derivative":{"exercise_price":1.96,"underlying":"Common Stock","underlying_shares":204080},"source":{"system":"sec-edgar","filing":"0001213900-25-011409","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390025011409/ownership.xml","form_type":"4"}},{"id":1278558,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to Purchase Shares of Common Stock","published_at":"2025-02-07T17:23:22.000Z","date":"2025-02-07","kind":"grant","planned":false,"acquired":true,"shares":306120,"price":1.9599,"value":599964.588,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 7, 2025, pursuant to a Securities Purchase Agreement, dated February 5, 2025, the reporting persons purchased Pre-Funded Warrants, which are exercisable at any time on or after the date of issuance for an exercise price of $0.0001 per share, for shares of common stock of CERo Therapeutics Holdings, Inc. (the \"Issuer\"), and an equal number of Warrants, which will become exercisable immediately upon the Issuer's receipt of stockholder approval (the \"Stockholder Approval Date\") for an exercise price of $1.96 per share, for shares of the Issuer's common stock. The aggregate purchase price for each pair of Pre-Funded Warrants and Warrants was $1.9599. The Warrants will expire on the fifth anniversary of the Stockholder Approval Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 7, 2025, pursuant to a Securities Purchase Agreement, dated February 5, 2025, the reporting persons purchased Pre-Funded Warrants, which are exercisable at any time on or after the date of issuance for an exercise price of $0.0001 per share, for shares of common stock of CERo Therapeutics Holdings, Inc. (the \"Issuer\"), and an equal number of Warrants, which will become exercisable immediately upon the Issuer's receipt of stockholder approval (the \"Stockholder Approval Date\") for an exercise price of $1.96 per share, for shares of the Issuer's common stock. The aggregate purchase price for each pair of Pre-Funded Warrants and Warrants was $1.9599. The Warrants will expire on the fifth anniversary of the Stockholder Approval Date."}],"balance_after":306120,"derivative":{"exercise_price":1.96,"underlying":"Common Stock","underlying_shares":306120},"source":{"system":"sec-edgar","filing":"0001213900-25-011409","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390025011409/ownership.xml","form_type":"4"}},{"id":1278557,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2025-02-07T17:23:22.000Z","date":"2025-02-07","kind":"grant","planned":false,"acquired":true,"shares":204080,"price":0.0001,"value":20.408,"ownership":{"direct":false,"nature":"By GVN, LLC"},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 7, 2025, pursuant to a Securities Purchase Agreement, dated February 5, 2025, the reporting persons purchased Pre-Funded Warrants, which are exercisable at any time on or after the date of issuance for an exercise price of $0.0001 per share, for shares of common stock of CERo Therapeutics Holdings, Inc. (the \"Issuer\"), and an equal number of Warrants, which will become exercisable immediately upon the Issuer's receipt of stockholder approval (the \"Stockholder Approval Date\") for an exercise price of $1.96 per share, for shares of the Issuer's common stock. The aggregate purchase price for each pair of Pre-Funded Warrants and Warrants was $1.9599. The Warrants will expire on the fifth anniversary of the Stockholder Approval Date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"GVN, LLC (the \"LLC\") is a limited liability company of which the sole member is the Atwood-Edminster Trust dtd 4-2-2000 (the \"Trust\"). Mr. Atwood and his wife are the managers of the LLC and the trustees of the Trust. Accordingly, Mr. Atwood may be deemed to have beneficial ownership of the securities held directly by the LLC."}],"balance_after":204080,"derivative":{"exercise_price":0.0001,"exercise_date":"2025-02-07","underlying":"Common Stock","underlying_shares":204080},"source":{"system":"sec-edgar","filing":"0001213900-25-011409","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390025011409/ownership.xml","form_type":"4"}},{"id":1278556,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2025-02-07T17:23:22.000Z","date":"2025-02-07","kind":"grant","planned":false,"acquired":true,"shares":306120,"price":0.0001,"value":30.612,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 7, 2025, pursuant to a Securities Purchase Agreement, dated February 5, 2025, the reporting persons purchased Pre-Funded Warrants, which are exercisable at any time on or after the date of issuance for an exercise price of $0.0001 per share, for shares of common stock of CERo Therapeutics Holdings, Inc. (the \"Issuer\"), and an equal number of Warrants, which will become exercisable immediately upon the Issuer's receipt of stockholder approval (the \"Stockholder Approval Date\") for an exercise price of $1.96 per share, for shares of the Issuer's common stock. The aggregate purchase price for each pair of Pre-Funded Warrants and Warrants was $1.9599. The Warrants will expire on the fifth anniversary of the Stockholder Approval Date."}],"balance_after":306120,"derivative":{"exercise_price":0.0001,"exercise_date":"2025-02-07","underlying":"Common Stock","underlying_shares":306120},"source":{"system":"sec-edgar","filing":"0001213900-25-011409","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390025011409/ownership.xml","form_type":"4"}},{"id":1332701,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":85096,"kind":"organization","name":"YK Bioventures Opportunities GP I, LLC","position":1,"cik":"0002042634","reported_name":"YK Bioventures Opportunities GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85097,"kind":"organization","name":"YK Bioventures Opportunities Fund I, L.P.","position":2,"cik":"0002042636","reported_name":"YK Bioventures Opportunities Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85098,"kind":"person","name":"Kossar Mitchell William","position":3,"cik":"0002042691","reported_name":"Kossar Mitchell William","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85099,"kind":"person","name":"Yeung Gary Kahing","position":4,"cik":"0002042700","reported_name":"Yeung Gary Kahing","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-13T18:41:13.000Z","date":"2024-12-13","kind":"sale","planned":false,"acquired":false,"shares":2998908,"price":0.06,"value":179934.48,"ownership":{"direct":false,"nature":"By YK Bioventures Opportunities Fund I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) (\"YK Opps I\"). YK Bioventures Opportunities GP I, LLC (\"YK Opps I GP\") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":13005169,"source":{"system":"sec-edgar","filing":"0001415889-24-029371","document":"form4-12132024_111210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2042636/000141588924029371/form4-12132024_111210.xml","form_type":"4"}},{"id":1332700,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":85096,"kind":"organization","name":"YK Bioventures Opportunities GP I, LLC","position":1,"cik":"0002042634","reported_name":"YK Bioventures Opportunities GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85097,"kind":"organization","name":"YK Bioventures Opportunities Fund I, L.P.","position":2,"cik":"0002042636","reported_name":"YK Bioventures Opportunities Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85098,"kind":"person","name":"Kossar Mitchell William","position":3,"cik":"0002042691","reported_name":"Kossar Mitchell William","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85099,"kind":"person","name":"Yeung Gary Kahing","position":4,"cik":"0002042700","reported_name":"Yeung Gary Kahing","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-13T18:41:13.000Z","date":"2024-12-12","kind":"sale","planned":false,"acquired":false,"shares":1614541,"price":0.07,"value":113017.87,"ownership":{"direct":false,"nature":"By YK Bioventures Opportunities Fund I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) (\"YK Opps I\"). YK Bioventures Opportunities GP I, LLC (\"YK Opps I GP\") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":16004077,"source":{"system":"sec-edgar","filing":"0001415889-24-029371","document":"form4-12132024_111210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2042636/000141588924029371/form4-12132024_111210.xml","form_type":"4"}},{"id":1332699,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":85096,"kind":"organization","name":"YK Bioventures Opportunities GP I, LLC","position":1,"cik":"0002042634","reported_name":"YK Bioventures Opportunities GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85097,"kind":"organization","name":"YK Bioventures Opportunities Fund I, L.P.","position":2,"cik":"0002042636","reported_name":"YK Bioventures Opportunities Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85098,"kind":"person","name":"Kossar Mitchell William","position":3,"cik":"0002042691","reported_name":"Kossar Mitchell William","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85099,"kind":"person","name":"Yeung Gary Kahing","position":4,"cik":"0002042700","reported_name":"Yeung Gary Kahing","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-13T18:41:13.000Z","date":"2024-12-11","kind":"sale","planned":false,"acquired":false,"shares":1343801,"price":0.08,"value":107504.08,"ownership":{"direct":false,"nature":"By YK Bioventures Opportunities Fund I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) (\"YK Opps I\"). YK Bioventures Opportunities GP I, LLC (\"YK Opps I GP\") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":17618618,"source":{"system":"sec-edgar","filing":"0001415889-24-029371","document":"form4-12132024_111210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042636/000141588924029371/form4-12132024_111210.xml","form_type":"4"}},{"id":1337514,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":85096,"kind":"organization","name":"YK Bioventures Opportunities GP I, LLC","position":1,"cik":"0002042634","reported_name":"YK Bioventures Opportunities GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85097,"kind":"organization","name":"YK Bioventures Opportunities Fund I, L.P.","position":2,"cik":"0002042636","reported_name":"YK Bioventures Opportunities Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85098,"kind":"person","name":"Kossar Mitchell William","position":3,"cik":"0002042691","reported_name":"Kossar Mitchell William","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85099,"kind":"person","name":"Yeung Gary Kahing","position":4,"cik":"0002042700","reported_name":"Yeung Gary Kahing","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-10T20:44:23.000Z","date":"2024-12-10","kind":"sale","planned":false,"acquired":false,"shares":1570947,"price":0.09,"value":141385.23,"ownership":{"direct":false,"nature":"By YK Bioventures Opportunities Fund I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) (\"YK Opps I\"). YK Bioventures Opportunities GP I, LLC (\"YK Opps I GP\") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":18962419,"source":{"system":"sec-edgar","filing":"0001415889-24-028899","document":"form4-12112024_011219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2042636/000141588924028899/form4-12112024_011219.xml","form_type":"4"}},{"id":1337513,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":85096,"kind":"organization","name":"YK Bioventures Opportunities GP I, LLC","position":1,"cik":"0002042634","reported_name":"YK Bioventures Opportunities GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85097,"kind":"organization","name":"YK Bioventures Opportunities Fund I, L.P.","position":2,"cik":"0002042636","reported_name":"YK Bioventures Opportunities Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85098,"kind":"person","name":"Kossar Mitchell William","position":3,"cik":"0002042691","reported_name":"Kossar Mitchell William","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85099,"kind":"person","name":"Yeung Gary Kahing","position":4,"cik":"0002042700","reported_name":"Yeung Gary Kahing","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-10T20:44:23.000Z","date":"2024-12-09","kind":"sale","planned":false,"acquired":false,"shares":850543,"price":0.11,"value":93559.73,"ownership":{"direct":false,"nature":"By YK Bioventures Opportunities Fund I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) (\"YK Opps I\"). YK Bioventures Opportunities GP I, LLC (\"YK Opps I GP\") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":20533366,"source":{"system":"sec-edgar","filing":"0001415889-24-028899","document":"form4-12112024_011219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2042636/000141588924028899/form4-12112024_011219.xml","form_type":"4"}},{"id":1337512,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":85096,"kind":"organization","name":"YK Bioventures Opportunities GP I, LLC","position":1,"cik":"0002042634","reported_name":"YK Bioventures Opportunities GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85097,"kind":"organization","name":"YK Bioventures Opportunities Fund I, L.P.","position":2,"cik":"0002042636","reported_name":"YK Bioventures Opportunities Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85098,"kind":"person","name":"Kossar Mitchell William","position":3,"cik":"0002042691","reported_name":"Kossar Mitchell William","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85099,"kind":"person","name":"Yeung Gary Kahing","position":4,"cik":"0002042700","reported_name":"Yeung Gary Kahing","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-10T20:44:23.000Z","date":"2024-12-06","kind":"sale","planned":false,"acquired":false,"shares":1236874,"price":0.12,"value":148424.88,"ownership":{"direct":false,"nature":"By YK Bioventures Opportunities Fund I, L.P."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) (\"YK Opps I\"). YK Bioventures Opportunities GP I, LLC (\"YK Opps I GP\") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":21383909,"source":{"system":"sec-edgar","filing":"0001415889-24-028899","document":"form4-12112024_011219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042636/000141588924028899/form4-12112024_011219.xml","form_type":"4"}},{"id":1343968,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-05T02:12:09.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 1, 2024, the Reporting Person was granted an option to purchase 255,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On December 2, 2024, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to one installment, resulting in the vesting of 127,500 shares."}],"balance_after":127500,"derivative":{"exercise_price":0.1,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0001213900-24-105728","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390024105728/ownership.xml","form_type":"4"}},{"id":1342741,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-04T21:13:32.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":1275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 1, 2024, the Reporting Person was granted an option to purchase 2,550,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On December 2, 2024, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to one installment, resulting in the vesting of 1,275,000 shares."}],"balance_after":1275000,"derivative":{"exercise_price":0.1,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":1275000},"source":{"system":"sec-edgar","filing":"0001213900-24-105730","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390024105730/ownership.xml","form_type":"4"}},{"id":1342460,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69617,"kind":"person","name":"Rolfe Lindsey","position":1,"cik":"0001650504","reported_name":"Rolfe Lindsey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-04T21:12:24.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 1, 2024, the Reporting Person was granted an option to purchase 255,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On December 2, 2024, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to one installment, resulting in the vesting of 127,500 shares."}],"balance_after":127500,"derivative":{"exercise_price":0.1,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0001213900-24-105729","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650504/000121390024105729/ownership.xml","form_type":"4"}},{"id":1342474,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-04T21:11:53.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 1, 2024, the Reporting Person was granted an option to purchase 255,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On December 2, 2024, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to one installment, resulting in the vesting of 127,500 shares."}],"balance_after":127500,"derivative":{"exercise_price":0.1,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0001213900-24-105727","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000121390024105727/ownership.xml","form_type":"4"}},{"id":1342728,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-04T21:11:38.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":254000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 1, 2024, the Reporting Person was granted an option to purchase 508,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On December 2, 2024, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to one installment, resulting in the vesting of 254,000 shares."}],"balance_after":254000,"derivative":{"exercise_price":0.1,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":254000},"source":{"system":"sec-edgar","filing":"0001213900-24-105726","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390024105726/ownership.xml","form_type":"4"}},{"id":1342748,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69655,"kind":"person","name":"Patel Shami","position":1,"cik":"0001378251","reported_name":"Patel Shami","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-04T21:10:55.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":127500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On October 11, 2024, the Reporting Person was granted an option to purchase 255,000 shares of Common Stock, which vest in two equal installments subject to the satisfaction of certain performance criteria. On December 2, 2024, the Issuer's Board of Directors confirmed that the performance criteria had been met with regards to one installment, resulting in the vesting of 127,500 shares."}],"balance_after":127500,"derivative":{"exercise_price":0.0951,"expiration_date":"2034-10-10","underlying":"Common Stock","underlying_shares":127500},"source":{"system":"sec-edgar","filing":"0001213900-24-105725","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1378251/000121390024105725/ownership.xml","form_type":"4"}},{"id":1357015,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":85860,"kind":"person","name":"SLOAN STUART M","position":1,"cik":"0001215280","reported_name":"SLOAN STUART M","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.0001 par value per share","published_at":"2024-11-20T16:04:56.000Z","date":"2024-09-25","kind":"sale","planned":false,"acquired":false,"shares":532486,"price":0.1043,"value":55538.2898,"ownership":{"direct":false,"nature":"By SMS Revocable Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades. the price reported above reflects the average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares of Common Stock are held of record and beneficially by SMS Revocable Trust. Stuart Sloan is the sole grantor and trustee of SMS Revocable Trust."}],"balance_after":21067956,"source":{"system":"sec-edgar","filing":"0001753926-24-001975","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1215280/000175392624001975/ownership.xml","form_type":"4"}},{"id":1365373,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":85096,"kind":"organization","name":"YK Bioventures Opportunities GP I, LLC","position":1,"cik":"0002042634","reported_name":"YK Bioventures Opportunities GP I, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85097,"kind":"organization","name":"YK Bioventures Opportunities Fund I, L.P.","position":2,"cik":"0002042636","reported_name":"YK Bioventures Opportunities Fund I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85098,"kind":"person","name":"Kossar Mitchell William","position":3,"cik":"0002042691","reported_name":"Kossar Mitchell William","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":85099,"kind":"person","name":"Yeung Gary Kahing","position":4,"cik":"0002042700","reported_name":"Yeung Gary Kahing","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-14T20:14:19.000Z","date":"2024-10-10","kind":"sale","planned":false,"acquired":false,"shares":3250000,"price":0.1,"value":325000.0,"ownership":{"direct":false,"nature":"By YK Bioventures Opportunities Fund I, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.09 to $0.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) (\"YK Opps I\"). YK Bioventures Opportunities GP I, LLC (\"YK Opps I GP\") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein."}],"balance_after":22620783,"source":{"system":"sec-edgar","filing":"0001415889-24-026908","document":"form4-11152024_011114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042636/000141588924026908/form4-11152024_011114.xml","form_type":"4"}},{"id":1395883,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-10-03T01:53:38.000Z","date":"2024-09-25","kind":"exercise","planned":false,"acquired":false,"shares":50,"price":1000,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":965997},"source":{"system":"sec-edgar","filing":"0001213900-24-084831","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390024084831/ownership.xml","form_type":"4"}},{"id":1395882,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T01:53:38.000Z","date":"2024-09-25","kind":"exercise","planned":false,"acquired":true,"shares":965997,"ownership":{"direct":false,"nature":"By the Kathleen LaPorte Revocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is the trustee of the Kathleen LaPorte Revocable Trust (the \"Trust\") and has sole voting and disposition power with respect to the shares owned by the Trust."}],"balance_after":965997,"source":{"system":"sec-edgar","filing":"0001213900-24-084831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390024084831/ownership.xml","form_type":"4"}},{"id":1393673,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":50834,"kind":"person","name":"KUCHARCHUK ANDREW ALBERT","position":1,"cik":"0001654127","reported_name":"KUCHARCHUK ANDREW ALBERT","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-02T23:03:10.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in twelve (12) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":500000,"derivative":{"exercise_price":0.1,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001213900-24-084759","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654127/000121390024084759/ownership.xml","form_type":"4"}},{"id":1394076,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Chairman and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-02T21:53:01.000Z","date":"2024-09-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":572182,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents the forfeiture of employee stock options in connection with the Reporting Person's appointment as Chief Executive Officer of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents the forfeiture of employee stock options in connection with the Reporting Person's appointment as Chief Executive Officer of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":1.77,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":572182},"source":{"system":"sec-edgar","filing":"0001213900-24-084830","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390024084830/ownership.xml","form_type":"4"}},{"id":1394075,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Chairman and CEO"}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-10-02T21:53:01.000Z","date":"2024-09-25","kind":"exercise","planned":false,"acquired":false,"shares":275,"price":1000,"value":275000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 275 shares of Series A Preferred Stock into 5,312,983 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 275 shares of Series A Preferred Stock into 5,312,983 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 275 shares of Series A Preferred Stock into 5,312,983 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 275 shares of Series A Preferred Stock into 5,312,983 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5312983},"source":{"system":"sec-edgar","filing":"0001213900-24-084830","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390024084830/ownership.xml","form_type":"4"}},{"id":1394074,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim Chairman and CEO"}}],"security":"Common Stock","published_at":"2024-10-02T21:53:01.000Z","date":"2024-09-25","kind":"exercise","planned":false,"acquired":true,"shares":5312983,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 275 shares of Series A Preferred Stock into 5,312,983 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 275 shares of Series A Preferred Stock into 5,312,983 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."}],"balance_after":5791808,"source":{"system":"sec-edgar","filing":"0001213900-24-084830","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390024084830/ownership.xml","form_type":"4"}},{"id":1393975,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-02T21:52:20.000Z","date":"2024-09-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1317956,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the forfeiture of employee stock options in connection with the Reporting Person's resignation as Chief Executive Officer of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents the forfeiture of employee stock options in connection with the Reporting Person's resignation as Chief Executive Officer of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":1.77,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":1317956},"source":{"system":"sec-edgar","filing":"0001213900-24-084829","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390024084829/ownership.xml","form_type":"4"}},{"id":1393974,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-02T21:52:20.000Z","date":"2024-09-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the forfeiture of employee stock options in connection with the Reporting Person's resignation as Chief Executive Officer of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents the forfeiture of employee stock options in connection with the Reporting Person's resignation as Chief Executive Officer of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":5.28,"expiration_date":"2030-12-27","underlying":"Common Stock","underlying_shares":13857},"source":{"system":"sec-edgar","filing":"0001213900-24-084829","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390024084829/ownership.xml","form_type":"4"}},{"id":1393973,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-10-02T21:52:20.000Z","date":"2024-09-25","kind":"exercise","planned":false,"acquired":false,"shares":1002,"price":1000,"value":1002000.0,"ownership":{"direct":false,"nature":"Atwood-Edminster Trust dtd 4-2-2000"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 1,002 shares of Series A Preferred Stock into 19,358,578 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 1,002 shares of Series A Preferred Stock into 19,358,578 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 1,002 shares of Series A Preferred Stock into 19,358,578 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 1,002 shares of Series A Preferred Stock into 19,358,578 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is the trustee of the Atwood-Edminster Trust dtd 4-2-2000 (the \"Atwood-Edminster Trust\") and has sole voting and disposition power with respect to the shares owned by the Atwood-Edminster Trust."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":19358578},"source":{"system":"sec-edgar","filing":"0001213900-24-084829","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390024084829/ownership.xml","form_type":"4"}},{"id":1393972,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-02T21:52:20.000Z","date":"2024-09-25","kind":"exercise","planned":false,"acquired":true,"shares":19358578,"ownership":{"direct":false,"nature":"Atwood-Edminster Trust dtd 4-2-2000"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 1,002 shares of Series A Preferred Stock into 19,358,578 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 25, 2024, the Reporting Person converted an aggregate of 1,002 shares of Series A Preferred Stock into 19,358,578 shares of Common Stock. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price of $1.00. As a result of various adjustments in the terms of the Series A Preferred Stock, each $1,000 of Series A Preferred Stock was converted into 19,320 shares of common stock. The Series A Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is the trustee of the Atwood-Edminster Trust dtd 4-2-2000 (the \"Atwood-Edminster Trust\") and has sole voting and disposition power with respect to the shares owned by the Atwood-Edminster Trust."}],"balance_after":19607313,"source":{"system":"sec-edgar","filing":"0001213900-24-084829","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390024084829/ownership.xml","form_type":"4"}},{"id":1394906,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69684,"kind":"person","name":"Pierce Kristen","position":1,"cik":"0002039649","reported_name":"Pierce Kristen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-02T19:02:27.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in twenty-four (24) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":200000,"derivative":{"exercise_price":0.1,"expiration_date":"2034-09-30","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001213900-24-084758","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2039649/000121390024084758/ownership.xml","form_type":"4"}},{"id":1465862,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":31451,"kind":"person","name":"Carter Charles Ross","position":1,"cik":"0001779359","reported_name":"Carter Charles Ross","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T20:01:02.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All of the shares underlying this option will vest on the date of the acceptance of an Investigational New Drug application by the U.S. Food and Drug Administration, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":0.3,"expiration_date":"2034-06-28","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-24-057868","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779359/000121390024057868/ownership.xml","form_type":"4"}},{"id":1559134,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":92597,"kind":"person","name":"Rapaport Robyn","position":1,"cik":"0002010809","reported_name":"Rapaport Robyn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-28T01:28:50.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in thirty-six (36) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":112500,"derivative":{"exercise_price":1.77,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001213900-24-026823","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024026823/ownership.xml","form_type":"4"}},{"id":1560067,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-28T01:28:26.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in thirty-six (36) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":112500,"derivative":{"exercise_price":1.77,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001213900-24-026822","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390024026822/ownership.xml","form_type":"4"}},{"id":1559563,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":31451,"kind":"person","name":"Carter Charles Ross","position":1,"cik":"0001779359","reported_name":"Carter Charles Ross","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-28T01:26:12.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":395387,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in forty-eight (48) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":395387,"derivative":{"exercise_price":1.77,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":395387},"source":{"system":"sec-edgar","filing":"0001213900-24-026818","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779359/000121390024026818/ownership.xml","form_type":"4"}},{"id":1559204,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69617,"kind":"person","name":"Rolfe Lindsey","position":1,"cik":"0001650504","reported_name":"Rolfe Lindsey","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T21:29:22.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in thirty-six (36) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":112500,"derivative":{"exercise_price":1.77,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001213900-24-026824","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650504/000121390024026824/ownership.xml","form_type":"4"}},{"id":1559397,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T21:27:56.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":572182,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in forty-eight (48) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":572182,"derivative":{"exercise_price":1.77,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":572182},"source":{"system":"sec-edgar","filing":"0001213900-24-026821","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390024026821/ownership.xml","form_type":"4"}},{"id":1559747,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":92621,"kind":"person","name":"Corey Daniel","position":1,"cik":"0002011547","reported_name":"Corey Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T21:27:21.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":856671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest as follows: 395,387 shares are immediately vested and exercisable, and the remainder shall vest in forty-eight (48) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":856671,"derivative":{"exercise_price":1.77,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":856671},"source":{"system":"sec-edgar","filing":"0001213900-24-026820","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2011547/000121390024026820/ownership.xml","form_type":"4"}},{"id":1559212,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69618,"kind":"person","name":"Byrnes Michael","position":1,"cik":"0001619893","reported_name":"Byrnes Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T21:24:57.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest in thirty-six (36) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":112500,"derivative":{"exercise_price":1.77,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001213900-24-026815","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1619893/000121390024026815/ownership.xml","form_type":"4"}},{"id":1559396,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T21:24:22.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":1317956,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest as follows: 732,198 shares are immediately vested and exercisable, and the remainder shall vest in forty-eight (48) monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":1317956,"derivative":{"exercise_price":1.77,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":1317956},"source":{"system":"sec-edgar","filing":"0001213900-24-026814","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390024026814/ownership.xml","form_type":"4"}},{"id":1583892,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-11T19:23:59.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":13857,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Atwood-Edminster Trust dtd 4-2-2000"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents an option to purchase the Issuer's Common Stock that was converted from the then outstanding CERo Therapeutics, Inc. option immediately prior to the consummation of the Issuer's business combination. The option is fully vested."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is the trustee of the Atwood-Edminster Trust dtd 4-2-2000 (the \"Atwood-Edminster Trust\") and has sole voting and disposition power with respect to the shares owned by the Atwood-Edminster Trust."}],"balance_after":13857,"derivative":{"exercise_price":5.28,"expiration_date":"2030-12-27","underlying":"Common Stock","underlying_shares":13857},"source":{"system":"sec-edgar","filing":"0001213900-24-021525","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390024021525/ownership.xml","form_type":"4/A","original_submission_date":"2024-02-16"}},{"id":1583891,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-03-11T19:23:59.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":1002,"price":1000,"value":1002000.0,"ownership":{"direct":false,"nature":"Atwood-Edminster Trust dtd 4-2-2000"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On February 14, 2024, the Atwood-Edminster Trust acquired 1,002 shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments (the \"Conversion Price\"). The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 14, 2024, the Atwood-Edminster Trust acquired 1,002 shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments (the \"Conversion Price\"). The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 14, 2024, the Atwood-Edminster Trust acquired 1,002 shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments (the \"Conversion Price\"). The Series A Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is the trustee of the Atwood-Edminster Trust dtd 4-2-2000 (the \"Atwood-Edminster Trust\") and has sole voting and disposition power with respect to the shares owned by the Atwood-Edminster Trust."}],"balance_after":1002,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":100200},"source":{"system":"sec-edgar","filing":"0001213900-24-021525","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390024021525/ownership.xml","form_type":"4/A","original_submission_date":"2024-02-16"}},{"id":1583890,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-11T19:23:59.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":true,"shares":148208,"ownership":{"direct":false,"nature":"Atwood-Edminster Trust dtd 4-2-2000"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Common Stock issued to the Atwood-Edminster Trust (as defined below) in connection with the Issuer's business combination consummated on February 14, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is the trustee of the Atwood-Edminster Trust dtd 4-2-2000 (the \"Atwood-Edminster Trust\") and has sole voting and disposition power with respect to the shares owned by the Atwood-Edminster Trust."}],"balance_after":248735,"source":{"system":"sec-edgar","filing":"0001213900-24-021525","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390024021525/ownership.xml","form_type":"4/A","original_submission_date":"2024-02-16"}},{"id":1583889,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-03-11T19:23:59.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":true,"shares":100527,"ownership":{"direct":false,"nature":"Atwood-Edminster Trust dtd 4-2-2000"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents earnout shares, each of which consist of one share of the Issuer's Common Stock, subject to forfeiture if certain vesting conditions are not satisfied. The earnout shares vest as follows: (i) 33,045 shares if the volume weighted average price (\"VWAP\") of the Common Stock for at least 20 of any 30 consecutive trading days following February 14, 2024 equals or exceeds the lesser of (x) $12.50 or (y) 125% of the then applicable conversion price; (ii) 33,045 shares shall vest if the VWAP for at least 20 of any 30 consecutive trading days following February 14, 2024 equals or exceeds the lesser of (x) $15.00 or (y) 150% of the then applicable conversion price; (iii) 13,218 shares shall vest upon a change of control; and (iv) 28,601 shares shall vest upon the Issuer's submission of an IND application to the FDA. If the vesting conditions are not met prior to February 14, 2028, the earnout shares will be cancelled."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents earnout shares, each of which consist of one share of the Issuer's Common Stock, subject to forfeiture if certain vesting conditions are not satisfied. The earnout shares vest as follows: (i) 33,045 shares if the volume weighted average price (\"VWAP\") of the Common Stock for at least 20 of any 30 consecutive trading days following February 14, 2024 equals or exceeds the lesser of (x) $12.50 or (y) 125% of the then applicable conversion price; (ii) 33,045 shares shall vest if the VWAP for at least 20 of any 30 consecutive trading days following February 14, 2024 equals or exceeds the lesser of (x) $15.00 or (y) 150% of the then applicable conversion price; (iii) 13,218 shares shall vest upon a change of control; and (iv) 28,601 shares shall vest upon the Issuer's submission of an IND application to the FDA. If the vesting conditions are not met prior to February 14, 2028, the earnout shares will be cancelled."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is the trustee of the Atwood-Edminster Trust dtd 4-2-2000 (the \"Atwood-Edminster Trust\") and has sole voting and disposition power with respect to the shares owned by the Atwood-Edminster Trust."}],"balance_after":100527,"source":{"system":"sec-edgar","filing":"0001213900-24-021525","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390024021525/ownership.xml","form_type":"4/A","original_submission_date":"2024-02-16"}},{"id":1631712,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-02-21T22:57:09.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":50,"price":1000,"value":50000.0,"ownership":{"direct":false,"nature":"By the Kathleen LaPorte Revocable Trust"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is the trustee of the Kathleen LaPorte Revocable Trust (the \"Kathleen Trust\") and has sole voting and disposition power with respect to the shares owned by the Kathleen Trust."}],"balance_after":50,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001213900-24-015876","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390024015876/ownership.xml","form_type":"4/A","original_submission_date":"2024-02-16"}},{"id":1628557,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-02-21T17:55:44.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":1002,"price":1000,"value":1002000.0,"ownership":{"direct":false,"nature":"Atwood-Edminster Trust dtd 4-2-2000"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On February 14, 2024, the Atwood-Edminster Trust acquired 1,002 shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments (the \"Conversion Price\"). The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On February 14, 2024, the Atwood-Edminster Trust acquired 1,002 shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments (the \"Conversion Price\"). The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On February 14, 2024, the Atwood-Edminster Trust acquired 1,002 shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments (the \"Conversion Price\"). The Series A Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is the trustee of the Atwood-Edminster Trust dtd 4-2-2000 (the \"Atwood-Edminster Trust\") and has sole voting and disposition power with respect to the shares owned by the Atwood-Edminster Trust."}],"balance_after":1002,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":100200},"source":{"system":"sec-edgar","filing":"0001213900-24-015874","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390024015874/ownership.xml","form_type":"4/A","original_submission_date":"2024-02-16"}},{"id":1628556,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-21T17:55:44.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":true,"shares":148208,"ownership":{"direct":false,"nature":"Atwood-Edminster Trust dtd 4-2-2000"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Common Stock issued to the Atwood-Edminster Trust (as defined below) in connection with the Issuer's business combination consummated on February 14, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is the trustee of the Atwood-Edminster Trust dtd 4-2-2000 (the \"Atwood-Edminster Trust\") and has sole voting and disposition power with respect to the shares owned by the Atwood-Edminster Trust."}],"balance_after":248735,"source":{"system":"sec-edgar","filing":"0001213900-24-015874","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390024015874/ownership.xml","form_type":"4/A","original_submission_date":"2024-02-16"}},{"id":1628555,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69648,"kind":"person","name":"ATWOOD BRIAN G","position":1,"cik":"0001266567","reported_name":"ATWOOD BRIAN G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-21T17:55:44.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":true,"shares":100527,"ownership":{"direct":false,"nature":"Atwood-Edminster Trust dtd 4-2-2000"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents earnout shares, each of which consist of one share of the Issuer's Common Stock, subject to forfeiture if certain vesting conditions are not satisfied. The earnout shares vest as follows: (i) 33,045 shares if the volume weighted average price (\"VWAP\") of the Common Stock for at least 20 of any 30 consecutive trading days following February 14, 2024 equals or exceeds the lesser of (x) $12.50 or (y) 125% of the then applicable conversion price; (ii) 33,045 shares shall vest if the VWAP for at least 20 of any 30 consecutive trading days following February 14, 2024 equals or exceeds the lesser of (x) $15.00 or (y) 150% of the then applicable conversion price; (iii) 13,218 shares shall vest upon a change of control; and (iv) 28,601 shares shall vest upon the Issuer's submission of an IND application to the FDA. If the vesting conditions are not met prior to February 14, 2028, the earnout shares will be cancelled."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents earnout shares, each of which consist of one share of the Issuer's Common Stock, subject to forfeiture if certain vesting conditions are not satisfied. The earnout shares vest as follows: (i) 33,045 shares if the volume weighted average price (\"VWAP\") of the Common Stock for at least 20 of any 30 consecutive trading days following February 14, 2024 equals or exceeds the lesser of (x) $12.50 or (y) 125% of the then applicable conversion price; (ii) 33,045 shares shall vest if the VWAP for at least 20 of any 30 consecutive trading days following February 14, 2024 equals or exceeds the lesser of (x) $15.00 or (y) 150% of the then applicable conversion price; (iii) 13,218 shares shall vest upon a change of control; and (iv) 28,601 shares shall vest upon the Issuer's submission of an IND application to the FDA. If the vesting conditions are not met prior to February 14, 2028, the earnout shares will be cancelled."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is the trustee of the Atwood-Edminster Trust dtd 4-2-2000 (the \"Atwood-Edminster Trust\") and has sole voting and disposition power with respect to the shares owned by the Atwood-Edminster Trust."}],"balance_after":100527,"source":{"system":"sec-edgar","filing":"0001213900-24-015874","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1266567/000121390024015874/ownership.xml","form_type":"4/A","original_submission_date":"2024-02-16"}},{"id":1637437,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":30683,"kind":"person","name":"Kosacz Barbara","position":1,"cik":"0001763316","reported_name":"Kosacz Barbara","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-02-17T00:40:38.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":true,"shares":5828,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of Class A Common Stock distributed in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members, pro rata and without consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Class A Common Stock distributed in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members, pro rata and without consideration."}],"balance_after":5828,"source":{"system":"sec-edgar","filing":"0001213900-24-015032","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763316/000121390024015032/ownership.xml","form_type":"4"}},{"id":1637377,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94202,"kind":"organization","name":"PHOENIX BIOTECH SPONSOR, LLC","position":1,"cik":"0001870407","reported_name":"PHOENIX BIOTECH SPONSOR, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2024-02-17T00:38:37.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":false,"shares":349998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by the reporting person to its members, pro rata and without consideration."}],"balance_after":0,"derivative":{"exercise_price":11.5,"exercise_date":"2024-03-15","expiration_date":"2029-02-14","underlying":"Common Stock","underlying_shares":349998},"source":{"system":"sec-edgar","filing":"0001213900-24-015028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024015028/ownership.xml","form_type":"4"}},{"id":1637376,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94202,"kind":"organization","name":"PHOENIX BIOTECH SPONSOR, LLC","position":1,"cik":"0001870407","reported_name":"PHOENIX BIOTECH SPONSOR, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-02-17T00:38:37.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":false,"shares":1555,"price":1000,"value":1555000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by the reporting person to its members, pro rata and without consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."}],"balance_after":0,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":155500},"source":{"system":"sec-edgar","filing":"0001213900-24-015028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024015028/ownership.xml","form_type":"4"}},{"id":1637375,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94202,"kind":"organization","name":"PHOENIX BIOTECH SPONSOR, LLC","position":1,"cik":"0001870407","reported_name":"PHOENIX BIOTECH SPONSOR, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-02-17T00:38:37.000Z","date":"2024-02-14","kind":"exercise","planned":false,"acquired":true,"shares":1555,"price":1000,"value":1555000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."}],"balance_after":1555,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":155500},"source":{"system":"sec-edgar","filing":"0001213900-24-015028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024015028/ownership.xml","form_type":"4"}},{"id":1637374,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94202,"kind":"organization","name":"PHOENIX BIOTECH SPONSOR, LLC","position":1,"cik":"0001870407","reported_name":"PHOENIX BIOTECH SPONSOR, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2024-02-17T00:38:37.000Z","date":"2024-02-14","kind":"exercise","planned":false,"acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."},{"field":"shares","element":"transactionShares","label":"F2","text":"Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Upon closing of the Issuer's initial business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."}],"balance_after":0,"derivative":{"exercise_price":10,"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001213900-24-015028","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024015028/ownership.xml","form_type":"4"}},{"id":1637373,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94202,"kind":"organization","name":"PHOENIX BIOTECH SPONSOR, LLC","position":1,"cik":"0001870407","reported_name":"PHOENIX BIOTECH SPONSOR, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-17T00:38:37.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":false,"shares":4171246,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by the reporting person to its members, pro rata and without consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by the reporting person to its members, pro rata and without consideration."}],"balance_after":1000000,"source":{"system":"sec-edgar","filing":"0001213900-24-015028","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024015028/ownership.xml","form_type":"4"}},{"id":1637372,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94202,"kind":"organization","name":"PHOENIX BIOTECH SPONSOR, LLC","position":1,"cik":"0001870407","reported_name":"PHOENIX BIOTECH SPONSOR, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-17T00:38:37.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":false,"shares":1125000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Represents shares of Common Stock forfeited to the Issuer for no consideration in connection with the Issuer's initial business combination."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents shares of Common Stock forfeited to the Issuer for no consideration in connection with the Issuer's initial business combination."}],"balance_after":4171246,"source":{"system":"sec-edgar","filing":"0001213900-24-015028","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024015028/ownership.xml","form_type":"4"}},{"id":1640070,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-02-17T00:37:58.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":50,"price":1000,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."}],"balance_after":50,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001213900-24-015027","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390024015027/ownership.xml","form_type":"4"}},{"id":1640069,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":29393,"kind":"person","name":"LAPORTE KATHLEEN","position":1,"cik":"0001196201","reported_name":"LAPORTE KATHLEEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-17T00:37:58.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":true,"shares":5828,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock, distributed in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members, pro rata and without consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of common stock, distributed in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members, pro rata and without consideration."}],"balance_after":5828,"source":{"system":"sec-edgar","filing":"0001213900-24-015027","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1196201/000121390024015027/ownership.xml","form_type":"4"}},{"id":1637749,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":89923,"kind":"person","name":"Loewy Caroline M","position":1,"cik":"0001367451","reported_name":"Loewy Caroline M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-02-16T19:41:23.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":true,"shares":5828,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of Class A Common Stock distributed in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members, pro rata and without consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Class A Common Stock distributed in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members, pro rata and without consideration."}],"balance_after":5828,"source":{"system":"sec-edgar","filing":"0001213900-24-015034","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1367451/000121390024015034/ownership.xml","form_type":"4"}},{"id":1637826,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":90815,"kind":"person","name":"Geffken Daniel E.","position":1,"cik":"0001314756","reported_name":"Geffken Daniel E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Class A Common Stock","published_at":"2024-02-16T19:39:38.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":true,"shares":10002,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of Class A Common Stock distributed in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members, pro rata and without consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Class A Common Stock distributed in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members, pro rata and without consideration."}],"balance_after":10002,"source":{"system":"sec-edgar","filing":"0001213900-24-015030","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1314756/000121390024015030/ownership.xml","form_type":"4"}},{"id":1637593,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94206,"kind":"person","name":"Fisher Douglas Carl","position":1,"cik":"0001572355","reported_name":"Fisher Douglas Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Warrants","published_at":"2024-02-16T19:39:11.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of Class A Common Stock or warrants, as applicable, distributed in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members, pro rata and without consideration."}],"balance_after":5000,"derivative":{"exercise_price":11.5,"exercise_date":"2024-03-15","expiration_date":"2029-02-14","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001213900-24-015029","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1572355/000121390024015029/ownership.xml","form_type":"4"}},{"id":1637592,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94206,"kind":"person","name":"Fisher Douglas Carl","position":1,"cik":"0001572355","reported_name":"Fisher Douglas Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-02-16T19:39:11.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":50,"price":1000,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 14, 2024, the reporting person acquired shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended. Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."}],"balance_after":50,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001213900-24-015029","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1572355/000121390024015029/ownership.xml","form_type":"4"}},{"id":1637591,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":94206,"kind":"person","name":"Fisher Douglas Carl","position":1,"cik":"0001572355","reported_name":"Fisher Douglas Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Class A Common Stock","published_at":"2024-02-16T19:39:11.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":true,"shares":43300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of Class A Common Stock or warrants, as applicable, distributed in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members, pro rata and without consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Class A Common Stock or warrants, as applicable, distributed in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members, pro rata and without consideration."}],"balance_after":43300,"source":{"system":"sec-edgar","filing":"0001213900-24-015029","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1572355/000121390024015029/ownership.xml","form_type":"4"}},{"id":1637993,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-02-16T19:37:06.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents (a) shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members without consideration and (b) shares of Common Stock issued by the Issuer to the Reporting Person in connection with the closing of the Issuer's business combination."}],"balance_after":5000,"derivative":{"exercise_price":11.5,"exercise_date":"2024-03-15","expiration_date":"2029-02-14","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001213900-24-015026","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390024015026/ownership.xml","form_type":"4"}},{"id":1637992,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants","published_at":"2024-02-16T19:37:06.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":false,"shares":349998,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Phoenix Biotech Sponsor, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents (a) shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members without consideration and (b) shares of Common Stock issued by the Issuer to the Reporting Person in connection with the closing of the Issuer's business combination."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by the Sponsor, which was previously managed by the reporting person. As of February 16, 2024, the reporting person was no longer the manager of the Sponsor. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":11.5,"exercise_date":"2024-03-15","expiration_date":"2029-02-14","underlying":"Common Stock","underlying_shares":349998},"source":{"system":"sec-edgar","filing":"0001213900-24-015026","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390024015026/ownership.xml","form_type":"4"}},{"id":1637991,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-02-16T19:37:06.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":true,"shares":175,"price":1000,"value":175000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents (a) shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members without consideration and (b) shares of Common Stock issued by the Issuer to the Reporting Person in connection with the closing of the Issuer's business combination."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."}],"balance_after":275,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001213900-24-015026","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390024015026/ownership.xml","form_type":"4"}},{"id":1637990,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-02-16T19:37:06.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":100,"price":1000,"value":100000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"On February 14, 2024, the reporting person acquired 100 shares of Series A Preferred Stock in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 5, 2024, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."}],"balance_after":100,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001213900-24-015026","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390024015026/ownership.xml","form_type":"4"}},{"id":1637989,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-02-16T19:37:06.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":false,"shares":1555,"price":1000,"value":1555000.0,"ownership":{"direct":false,"nature":"By Phoenix Biotech Sponsor, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents (a) shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members without consideration and (b) shares of Common Stock issued by the Issuer to the Reporting Person in connection with the closing of the Issuer's business combination."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by the Sponsor, which was previously managed by the reporting person. As of February 16, 2024, the reporting person was no longer the manager of the Sponsor. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":155500},"source":{"system":"sec-edgar","filing":"0001213900-24-015026","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390024015026/ownership.xml","form_type":"4"}},{"id":1637988,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-02-16T19:37:06.000Z","date":"2024-02-14","kind":"exercise","planned":false,"acquired":true,"shares":1555,"price":1000,"value":1555000.0,"ownership":{"direct":false,"nature":"By Phoenix Biotech Sponsor, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Upon closing of the Issuer's business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series A Preferred Stock has a stated value of $1,000 and, at the option of the holder, is convertible into a number of shares of Common Stock determined by dividing (x) the value of the shares of Series A Preferred Stock, plus any additional amounts thereon as of such date of determination, by (y) the conversion price, which is currently $10.00, subject to adjustments. The Series A Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by the Sponsor, which was previously managed by the reporting person. As of February 16, 2024, the reporting person was no longer the manager of the Sponsor. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose."}],"balance_after":1555,"derivative":{"exercise_price":10,"underlying":"Common Stock","underlying_shares":155500},"source":{"system":"sec-edgar","filing":"0001213900-24-015026","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390024015026/ownership.xml","form_type":"4"}},{"id":1637987,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Promissory Note","published_at":"2024-02-16T19:37:06.000Z","date":"2024-02-14","kind":"exercise","planned":false,"acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Phoenix Biotech Sponsor, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Upon closing of the Issuer's business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."},{"field":"shares","element":"transactionShares","label":"F3","text":"Upon closing of the Issuer's business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon closing of the Issuer's business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon closing of the Issuer's business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Upon closing of the Issuer's business combination, the aggregate principal amount of the Convertible Promissory Note converted into shares of Series A Convertible Preferred Stock (the \"Series A Preferred Stock\") at a conversion price equal to $10.00."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held directly by the Sponsor, which was previously managed by the reporting person. As of February 16, 2024, the reporting person was no longer the manager of the Sponsor. The reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":10,"underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001213900-24-015026","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390024015026/ownership.xml","form_type":"4"}},{"id":1637986,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-16T19:37:06.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":true,"shares":3600,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents (a) shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members without consideration and (b) shares of Common Stock issued by the Issuer to the Reporting Person in connection with the closing of the Issuer's business combination."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents (a) shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members without consideration and (b) shares of Common Stock issued by the Issuer to the Reporting Person in connection with the closing of the Issuer's business combination."}],"balance_after":3600,"source":{"system":"sec-edgar","filing":"0001213900-24-015026","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390024015026/ownership.xml","form_type":"4"}},{"id":1637985,"issuer":{"id":8622,"kind":"organization","name":"CERO THERAPEUTICS HOLDINGS, INC."},"owners":[{"id":69653,"kind":"person","name":"Ehrlich Christopher B","position":1,"cik":"0001293973","reported_name":"Ehrlich Christopher B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-16T19:37:06.000Z","date":"2024-02-14","kind":"other","planned":false,"acquired":true,"shares":478825,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents (a) shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members without consideration and (b) shares of Common Stock issued by the Issuer to the Reporting Person in connection with the closing of the Issuer's business combination."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents (a) shares of Common Stock, Series A Preferred Stock or warrants, as applicable, distributed-in-kind by Phoenix Biotech Sponsor, LLC (the \"Sponsor\") to its members without consideration and (b) shares of Common Stock issued by the Issuer to the Reporting Person in connection with the closing of the Issuer's business combination."}],"balance_after":478825,"source":{"system":"sec-edgar","filing":"0001213900-24-015026","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1293973/000121390024015026/ownership.xml","form_type":"4"}}],"next_cursor":"2024-02-16T19:37:06.000000Z,1637985"}